{
  "run": {
    "id": "cmnr13fv703epp6589lhbdflh",
    "region": "US",
    "assetId": "cmnr13fu103ekp658rhhwwz7i",
    "ticker": "DXCM",
    "snapshotId": "cmnr13fub03emp658feuoxf4o",
    "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux",
    "createdAt": "2026-04-09T05:20:30.734Z",
    "promptTemplate": {
      "id": "cmnqt07si0005lm3jzpxuu1ux",
      "name": "Oficial 08.apr.2026",
      "version": 1
    },
    "snapshot": {
      "id": "cmnr13fub03emp658feuoxf4o",
      "assetId": "cmnr13fu103ekp658rhhwwz7i",
      "asOf": "2026-04-08T20:00:02.000Z",
      "snapshot": {
        "asOf": "2026-04-08T20:00:02.000Z",
        "quote": {
          "asOf": "2026-04-08T20:00:02.000Z",
          "open": null,
          "price": 65.8,
          "dayLow": 64.86,
          "volume": 2807911,
          "dayHigh": 65.87,
          "currency": "USD",
          "prevClose": 63.11,
          "week52Low": 54.11,
          "week52High": 89.98
        },
        "fundamentals": {
          "pe": 83.8984375,
          "beta": 0.940603210962267,
          "epsTTM": 1.6,
          "fcfTTM": 54000000,
          "growth": {
            "epsYoy": 0.4657534246575344,
            "revenueYoy": 0.1559633027522936
          },
          "sector": "Surgical & Medical Instruments & Apparatus",
          "margins": {
            "net": 0.1793865293865294,
            "gross": 0.601008151008151,
            "operating": 0.1955812955812956
          },
          "website": "http://dexcom.com",
          "industry": null,
          "pegRatio": -1.20878465048209,
          "ebitdaTTM": 373800000,
          "forwardPe": 114.732905982906,
          "marketCap": 34200000000,
          "totalCash": 395600000,
          "totalDebt": 1047100000,
          "debtEquity": 1.370011775480832,
          "quickRatio": 1.955645161290323,
          "revenueTTM": 4662000000,
          "companyName": "DEXCOM INC",
          "priceToBook": 5.76538585387519,
          "currentRatio": 5.631823821339951,
          "dividendYield": null,
          "returnOnAssets": 0.3826234158393192,
          "returnOnEquity": 0.0687097490561848,
          "analystOpinions": null,
          "businessSummary": "Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A., and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia; and Athenry, County Galway, Ireland.",
          "enterpriseValue": null,
          "analystTargetLow": null,
          "analystTargetHigh": null,
          "analystTargetMean": null,
          "fullTimeEmployees": 11100,
          "sharesOutstanding": 384864842,
          "enterpriseToEbitda": null,
          "analystTargetMedian": null,
          "enterpriseToRevenue": null,
          "operatingCashflowTTM": 1440700000,
          "analystRecommendationKey": null
        }
      },
      "createdAt": "2026-04-09T05:20:30.708Z"
    },
    "results": [
      {
        "id": "cmnr13fva03erp658ymp6t46y",
        "runId": "cmnr13fv703epp6589lhbdflh",
        "modelId": "anthropic",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"DXCM\",\"currency\":\"USD\",\"current_price\":65.8,\"target_price_6m\":72.0,\"target_price_12m\":78.0,\"recommendation\":\"BUY\",\"confidence\":0.58,\"thesis_bullets\":[\"CGM market secular growth supports mid-teens revenue expansion trajectory\",\"Operating margin at ~19.6% has room for expansion toward 22%+ with scale\",\"Stock trades near 52-week low offering better entry vs prior premium\",\"Heavy capex phase depresses FCF but OCF of $1.44B signals strong core economics\",\"Valuation remains elevated at ~84x PE requiring sustained execution to justify\"],\"key_drivers\":[{\"driver\":\"Type 2 diabetes CGM adoption expanding addressable market\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"International market penetration still early innings\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Manufacturing scale-up in Malaysia and Ireland improving unit economics\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Revenue YoY growth of 15.6% shows solid demand momentum\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Forward PE of 115x signals market expects near-term earnings headwinds\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"GLP-1 drugs could reduce future diabetes prevalence\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Abbott Libre and Medtronic intensifying competitive pressure\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Debt/equity at 1.37 elevated for a medtech growth company\",\"impact\":\"LOW\",\"direction\":\"NEG\"},{\"driver\":\"FCF TTM only $54M vs $34B market cap is extremely thin\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Abbott Libre price competition compresses CGM ASPs and margins\",\"GLP-1 agonist adoption materially shrinks diabetes patient population\",\"Payer reimbursement tightens for CGM devices in key markets\",\"Forward PE divergence from trailing PE suggests upcoming earnings miss risk\",\"Regulatory delays on next-gen sensor launches\"],\"assumptions\":{\"revenue_cagr_3y\":0.13,\"ebit_margin_target\":0.22,\"wacc\":0.095,\"terminal_multiple\":22.0},\"scenarios\":{\"bear\":{\"target_price\":55.0,\"prob\":0.25,\"notes\":\"CGM pricing war with Abbott, GLP-1 headwinds crimp growth to single digits.\"},\"base\":{\"target_price\":78.0,\"prob\":0.50,\"notes\":\"Mid-teens revenue growth continues, margin expansion to ~22%, multiple compresses modestly.\"},\"bull\":{\"target_price\":96.0,\"prob\":0.25,\"notes\":\"Type 2 adoption accelerates globally, margins exceed 24%, sentiment re-rates higher.\"}},\"method_notes\":\"Valuation via forward EV/EBIT: 3Y revenue CAGR 13% yields ~$6.7B rev, 22% EBIT margin = ~$1.48B EBIT, 22x multiple = ~$32.5B EV, minus net debt ~$0.65B, /385M shares ≈ $83 intrinsic. Discounted back ~1yr at WACC gives ~$78 12M target. High PE and low FCF yield temper conviction. Sell-side targets noted but not used as numeric inputs. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "ai-equity-research-v1",
          "risks": [
            "Abbott Libre price competition compresses CGM ASPs and margins",
            "GLP-1 agonist adoption materially shrinks diabetes patient population",
            "Payer reimbursement tightens for CGM devices in key markets",
            "Forward PE divergence from trailing PE suggests upcoming earnings miss risk",
            "Regulatory delays on next-gen sensor launches"
          ],
          "ticker": "DXCM",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Mid-teens revenue growth continues, margin expansion to ~22%, multiple compresses modestly.",
              "target_price": 78
            },
            "bear": {
              "prob": 0.25,
              "notes": "CGM pricing war with Abbott, GLP-1 headwinds crimp growth to single digits.",
              "target_price": 55
            },
            "bull": {
              "prob": 0.25,
              "notes": "Type 2 adoption accelerates globally, margins exceed 24%, sentiment re-rates higher.",
              "target_price": 96
            }
          },
          "confidence": 0.58,
          "assumptions": {
            "wacc": 0.095,
            "revenue_cagr_3y": 0.13,
            "terminal_multiple": 22,
            "ebit_margin_target": 0.22
          },
          "key_drivers": [
            {
              "driver": "Type 2 diabetes CGM adoption expanding addressable market",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "International market penetration still early innings",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Manufacturing scale-up in Malaysia and Ireland improving unit economics",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Revenue YoY growth of 15.6% shows solid demand momentum",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Forward PE of 115x signals market expects near-term earnings headwinds",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "GLP-1 drugs could reduce future diabetes prevalence",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Abbott Libre and Medtronic intensifying competitive pressure",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Debt/equity at 1.37 elevated for a medtech growth company",
              "impact": "LOW",
              "direction": "NEG"
            },
            {
              "driver": "FCF TTM only $54M vs $34B market cap is extremely thin",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Valuation via forward EV/EBIT: 3Y revenue CAGR 13% yields ~$6.7B rev, 22% EBIT margin = ~$1.48B EBIT, 22x multiple = ~$32.5B EV, minus net debt ~$0.65B, /385M shares ≈ $83 intrinsic. Discounted back ~1yr at WACC gives ~$78 12M target. High PE and low FCF yield temper conviction. Sell-side targets noted but not used as numeric inputs. Not investment advice.",
          "current_price": 65.8,
          "recommendation": "BUY",
          "thesis_bullets": [
            "CGM market secular growth supports mid-teens revenue expansion trajectory",
            "Operating margin at ~19.6% has room for expansion toward 22%+ with scale",
            "Stock trades near 52-week low offering better entry vs prior premium",
            "Heavy capex phase depresses FCF but OCF of $1.44B signals strong core economics",
            "Valuation remains elevated at ~84x PE requiring sustained execution to justify"
          ],
          "target_price_6m": 72,
          "target_price_12m": 78
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "anthropic",
            "webSearch": {
              "enabled": false,
              "maxToolCalls": 2,
              "disabledReason": null
            },
            "pauseTurns": 0,
            "stopReason": "end_turn"
          },
          "sanityIssues": []
        },
        "latencyMs": 45086,
        "createdAt": "2026-04-09T05:20:30.734Z",
        "usage": {
          "inputTokens": 3588,
          "outputTokens": 2084,
          "costUsd": 0.07004
        }
      },
      {
        "id": "cmnr13fva03eup6589lt28zov",
        "runId": "cmnr13fv703epp6589lhbdflh",
        "modelId": "deepseek.reasoner",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"AI Equity Research Model\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"DXCM\",\n  \"currency\": \"USD\",\n  \"current_price\": 65.8,\n  \"target_price_6m\": 72.0,\n  \"target_price_12m\": 78.0,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.65,\n  \"thesis_bullets\": [\n    \"Strong revenue growth from CGM adoption.\",\n    \"High operating margins support earnings.\",\n    \"Valuation high but justified by growth.\",\n    \"International markets offer expansion.\",\n    \"Risks from competition and regulation.\"\n  ],\n  \"key_drivers\": [\n    {\"driver\": \"Increasing diabetes prevalence\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n    {\"driver\": \"New product innovation\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n    {\"driver\": \"Insurance reimbursement trends\", \"impact\": \"MED\", \"direction\": \"POS\"},\n    {\"driver\": \"Competitive intensity\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n    {\"driver\": \"Regulatory environment\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n    {\"driver\": \"Cost management\", \"impact\": \"LOW\", \"direction\": \"NEG\"},\n    {\"driver\": \"Debt and liquidity\", \"impact\": \"LOW\", \"direction\": \"NEG\"},\n    {\"driver\": \"Market share dynamics\", \"impact\": \"HIGH\", \"direction\": \"POS\"}\n  ],\n  \"risks\": [\"Increased competition from Abbott\", \"Regulatory changes impacting pricing\", \"Execution risks in global expansion\", \"Technological advancements by rivals\", \"Economic sensitivity\"],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.12,\n    \"ebit_margin_target\": 0.20,\n    \"wacc\": 0.09,\n    \"terminal_multiple\": 25.0\n  },\n  \"scenarios\": {\n    \"bear\": {\"target_price\": 60.0, \"prob\": 0.2, \"notes\": \"Slower growth and multiple contraction.\"},\n    \"base\": {\"target_price\": 78.0, \"prob\": 0.6, \"notes\": \"Steady execution and moderate growth.\"},\n    \"bull\": {\"target_price\": 90.0, \"prob\": 0.2, \"notes\": \"Accelerated adoption and expansion.\"}\n  },\n  \"method_notes\": \"Valuation based on forward earnings and growth assumptions. BUY due to upside with balanced risks. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "AI Equity Research Model",
          "risks": [
            "Increased competition from Abbott",
            "Regulatory changes impacting pricing",
            "Execution risks in global expansion",
            "Technological advancements by rivals",
            "Economic sensitivity"
          ],
          "ticker": "DXCM",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Steady execution and moderate growth.",
              "target_price": 78
            },
            "bear": {
              "prob": 0.2,
              "notes": "Slower growth and multiple contraction.",
              "target_price": 60
            },
            "bull": {
              "prob": 0.2,
              "notes": "Accelerated adoption and expansion.",
              "target_price": 90
            }
          },
          "confidence": 0.65,
          "assumptions": {
            "wacc": 0.09,
            "revenue_cagr_3y": 0.12,
            "terminal_multiple": 25,
            "ebit_margin_target": 0.2
          },
          "key_drivers": [
            {
              "driver": "Increasing diabetes prevalence",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "New product innovation",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Insurance reimbursement trends",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Competitive intensity",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Regulatory environment",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Cost management",
              "impact": "LOW",
              "direction": "NEG"
            },
            {
              "driver": "Debt and liquidity",
              "impact": "LOW",
              "direction": "NEG"
            },
            {
              "driver": "Market share dynamics",
              "impact": "HIGH",
              "direction": "POS"
            }
          ],
          "method_notes": "Valuation based on forward earnings and growth assumptions. BUY due to upside with balanced risks. Not investment advice.",
          "current_price": 65.8,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Strong revenue growth from CGM adoption.",
            "High operating margins support earnings.",
            "Valuation high but justified by growth.",
            "International markets offer expansion.",
            "Risks from competition and regulation."
          ],
          "target_price_6m": 72,
          "target_price_12m": 78
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "endpoint": "https://api.deepseek.com/v1/chat/completions",
            "provider": "deepseek",
            "webSearch": {
              "enabled": false,
              "supported": false
            },
            "responseFormat": "json_object"
          },
          "sanityIssues": []
        },
        "latencyMs": 347,
        "createdAt": "2026-04-09T05:20:30.734Z",
        "usage": {
          "inputTokens": 2088,
          "outputTokens": 5098,
          "costUsd": 0.002726
        }
      },
      {
        "id": "cmnr13fva03esp658xzlvbrz1",
        "runId": "cmnr13fv703epp6589lhbdflh",
        "modelId": "gemini.3-pro",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"Equity Research v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"DXCM\",\"currency\":\"USD\",\"current_price\":65.8,\"target_price_6m\":72.0,\"target_price_12m\":78.0,\"recommendation\":\"BUY\",\"confidence\":0.65,\"thesis_bullets\":[\"G7 sensor adoption drives market share gains in the intensive insulin-delivery segment.\",\"Stelo launch opens a massive TAM in the non-insulin-using Type 2 population.\",\"International expansion remains a significant long-term growth lever for the CGM ecosystem.\",\"Operating leverage improves as G7 manufacturing scales and automated lines mature.\",\"GLP-1 drugs are complementary as CGM remains vital for metabolic health monitoring.\"],\"key_drivers\":[{\"driver\":\"G7 adoption rate\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Stelo OTC sales volume\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Competitive pricing from Abbott\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"GLP-1 drug penetration\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"International reimbursement wins\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Manufacturing automation efficiency\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Intense pricing competition from Abbott's FreeStyle Libre system.\",\"Potential disruption from non-invasive glucose monitoring technologies.\",\"Slower than expected adoption of OTC products like Stelo.\",\"Changes in global healthcare reimbursement policies for CGM.\"],\"assumptions\":{\"revenue_cagr_3y\":0.18,\"ebit_margin_target\":0.25,\"wacc\":0.09,\"terminal_multiple\":35.0},\"scenarios\":{\"bear\":{\"target_price\":55.0,\"prob\":0.25,\"notes\":\"Pricing war and GLP-1 adoption reduce CGM demand.\"},\"base\":{\"target_price\":78.0,\"prob\":0.5,\"notes\":\"Steady G7 growth and successful Stelo market entry.\"},\"bull\":{\"target_price\":95.0,\"prob\":0.25,\"notes\":\"Rapid international expansion and high OTC consumer adoption.\"}},\"method_notes\":\"Valuation based on 12M forward EV/EBITDA and DCF. BUY reflects ~18% upside. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "Equity Research v1",
          "risks": [
            "Intense pricing competition from Abbott's FreeStyle Libre system.",
            "Potential disruption from non-invasive glucose monitoring technologies.",
            "Slower than expected adoption of OTC products like Stelo.",
            "Changes in global healthcare reimbursement policies for CGM."
          ],
          "ticker": "DXCM",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Steady G7 growth and successful Stelo market entry.",
              "target_price": 78
            },
            "bear": {
              "prob": 0.25,
              "notes": "Pricing war and GLP-1 adoption reduce CGM demand.",
              "target_price": 55
            },
            "bull": {
              "prob": 0.25,
              "notes": "Rapid international expansion and high OTC consumer adoption.",
              "target_price": 95
            }
          },
          "confidence": 0.65,
          "assumptions": {
            "wacc": 0.09,
            "revenue_cagr_3y": 0.18,
            "terminal_multiple": 35,
            "ebit_margin_target": 0.25
          },
          "key_drivers": [
            {
              "driver": "G7 adoption rate",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Stelo OTC sales volume",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Competitive pricing from Abbott",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "GLP-1 drug penetration",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "International reimbursement wins",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Manufacturing automation efficiency",
              "impact": "MED",
              "direction": "POS"
            }
          ],
          "method_notes": "Valuation based on 12M forward EV/EBITDA and DCF. BUY reflects ~18% upside. Not investment advice.",
          "current_price": 65.8,
          "recommendation": "BUY",
          "thesis_bullets": [
            "G7 sensor adoption drives market share gains in the intensive insulin-delivery segment.",
            "Stelo launch opens a massive TAM in the non-insulin-using Type 2 population.",
            "International expansion remains a significant long-term growth lever for the CGM ecosystem.",
            "Operating leverage improves as G7 manufacturing scales and automated lines mature.",
            "GLP-1 drugs are complementary as CGM remains vital for metabolic health monitoring."
          ],
          "target_price_6m": 72,
          "target_price_12m": 78
        },
        "errorsJson": {
          "attempts": [
            {
              "error": "not_json_object: Output must be a single JSON object (no markdown/code fences, no extra text).",
              "attempt": 0,
              "rawOutputTruncated": "{\"model\":\"Equity Research v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"DXCM\",\"currency\":\"USD\",\"current_price\":65.8,\"target_price_6m\":72.0,\"target_price_12m\":78.0,\"recommendation\":\"BUY\",\"confidence\":0.65,\"thesis_bullets\":[\"G7 sensor adoption continues to drive market share gains in the intensive insulin-delivery segment.\",\"Stelo launch opens a massive TAM in the non-insulin-using Type 2 diabetes population.\",\"International expansion remains a significant long-term growth lever for the CGM ecosystem.\",\"Operating leverage is expected to improve as G7 manufacturing scales and automated lines mature.\",\"GLP-1 concerns are overblown as CGM remains complementary for metabolic health monitoring.\"],\"key_drivers\":[{\"driver\":\"G7 adoption rate\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Stelo OTC sales volume\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Competitive pricing from Abbott\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"GLP-1 drug penetration\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"International reimbursement wins\",\""
            },
            {
              "error": "not_json_object: Output must be a single JSON object (no markdown/code fences, no extra text).",
              "attempt": 1,
              "rawOutputTruncated": "{\"model\":\"Equity Research v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"DXCM\",\"currency\":\"USD\",\"current_price\":65.8,\"target_price_6m\":72.0,\"target_price_12m\":78.0,\"recommendation\":\"BUY\",\"confidence\":0.65,\"thesis_bullets\":[\"G7 sensor adoption continues to drive market share gains in the intensive insulin-delivery segment.\",\"Stelo launch opens a massive TAM in the non-insulin-using Type 2 diabetes population.\",\"International expansion remains a significant long-term growth lever for the CGM ecosystem.\",\"Operating leverage is expected to improve as G7 manufacturing scales and automated lines mature.\",\"GLP-1 concerns are overblown as CGM remains complementary for metabolic health monitoring.\"],\"key_drivers\":[{\"driver\":\"G7 adoption rate\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Stelo OTC sales volume\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Competitive pricing from Abbott\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"GLP-1 drug penetration\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"International reimbursement wins\",\"impact\":\"MED\",\""
            }
          ],
          "providerMeta": {
            "model": "gemini-3-flash-preview",
            "provider": "gemini",
            "webSearch": {
              "used": false,
              "allowed": false,
              "enabled": false,
              "requested": false,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 16670,
        "createdAt": "2026-04-09T05:20:30.734Z",
        "usage": {
          "inputTokens": 2730,
          "outputTokens": 505,
          "costUsd": 0.01152
        }
      },
      {
        "id": "cmnr13fva03eqp658lcmrposx",
        "runId": "cmnr13fv703epp6589lhbdflh",
        "modelId": "openai.gpt-5.4",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"DXCM\",\"currency\":\"USD\",\"current_price\":65.8,\"target_price_6m\":68.2,\"target_price_12m\":69.0,\"recommendation\":\"HOLD\",\"confidence\":0.63,\"thesis_bullets\":[\"CGM penetration remains underpenetrated, supporting double-digit medium-term revenue growth.\",\"G7 and Stelo broaden Dexcom's reach beyond intensive insulin users.\",\"Abbott competition and pricing pressure limit margin expansion and upside.\",\"Free cash flow is currently weak relative to reported earnings and cash flow.\",\"Risk/reward looks balanced after the pullback, supporting only modest upside.\"],\"key_drivers\":[{\"driver\":\"CGM category penetration\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"G7 adoption and upgrades\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Stelo OTC traction\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Type 2 reimbursement expansion\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Abbott pricing competition\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Gross margin recovery\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Manufacturing scale-up risk\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"International expansion\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Aggressive Abbott pricing erodes share and margins\",\"Reimbursement tightening in Type 2 diabetes\",\"Manufacturing or sensor quality issues\",\"OTC CGM adoption below expectations\",\"High valuation de-rates on slower growth\"],\"assumptions\":{\"revenue_cagr_3y\":13,\"ebit_margin_target\":22,\"wacc\":8.8,\"terminal_multiple\":23},\"scenarios\":{\"bear\":{\"target_price\":55,\"prob\":0.25,\"notes\":\"Libre pricing pressure and weaker Type 2 uptake drive multiple compression.\"},\"base\":{\"target_price\":69,\"prob\":0.5,\"notes\":\"Double-digit growth continues, but margin recovery is gradual.\"},\"bull\":{\"target_price\":84,\"prob\":0.25,\"notes\":\"Stelo, G7, and broader coverage accelerate growth and sentiment.\"}},\"method_notes\":\"12M target uses a blended forward EV/EBIT and discounted 3Y EBIT framework from snapshot financials; quote fields kept exactly from snapshot. No sell-side targets used. Mixed growth strength and valuation/competition pressure support HOLD. not investment advice\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "OpenAI o3",
          "risks": [
            "Aggressive Abbott pricing erodes share and margins",
            "Reimbursement tightening in Type 2 diabetes",
            "Manufacturing or sensor quality issues",
            "OTC CGM adoption below expectations",
            "High valuation de-rates on slower growth"
          ],
          "ticker": "DXCM",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Double-digit growth continues, but margin recovery is gradual.",
              "target_price": 69
            },
            "bear": {
              "prob": 0.25,
              "notes": "Libre pricing pressure and weaker Type 2 uptake drive multiple compression.",
              "target_price": 55
            },
            "bull": {
              "prob": 0.25,
              "notes": "Stelo, G7, and broader coverage accelerate growth and sentiment.",
              "target_price": 84
            }
          },
          "confidence": 0.63,
          "assumptions": {
            "wacc": 8.8,
            "revenue_cagr_3y": 13,
            "terminal_multiple": 23,
            "ebit_margin_target": 22
          },
          "key_drivers": [
            {
              "driver": "CGM category penetration",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "G7 adoption and upgrades",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Stelo OTC traction",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Type 2 reimbursement expansion",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Abbott pricing competition",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Gross margin recovery",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Manufacturing scale-up risk",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "International expansion",
              "impact": "MED",
              "direction": "POS"
            }
          ],
          "method_notes": "12M target uses a blended forward EV/EBIT and discounted 3Y EBIT framework from snapshot financials; quote fields kept exactly from snapshot. No sell-side targets used. Mixed growth strength and valuation/competition pressure support HOLD. not investment advice",
          "current_price": 65.8,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "CGM penetration remains underpenetrated, supporting double-digit medium-term revenue growth.",
            "G7 and Stelo broaden Dexcom's reach beyond intensive insulin users.",
            "Abbott competition and pricing pressure limit margin expansion and upside.",
            "Free cash flow is currently weak relative to reported earnings and cash flow.",
            "Risk/reward looks balanced after the pullback, supporting only modest upside."
          ],
          "target_price_6m": 68.2,
          "target_price_12m": 69
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "openai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "resp_0acb252171eec61a0069d75862d8488197a28ebe8fccc8576c",
            "reasoningEffort": "medium",
            "structuredOutputs": {
              "used": true,
              "requested": true,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 50860,
        "createdAt": "2026-04-09T05:20:30.734Z",
        "usage": {
          "inputTokens": 2358,
          "outputTokens": 2560,
          "costUsd": 0.039966
        }
      },
      {
        "id": "cmnr13fva03etp6589gj9x9n0",
        "runId": "cmnr13fv703epp6589lhbdflh",
        "modelId": "xai.grok-4.20-reasoning",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"AI Equity Research Model\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"DXCM\",\n  \"currency\": \"USD\",\n  \"current_price\": 65.8,\n  \"target_price_6m\": 74,\n  \"target_price_12m\": 82,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.61,\n  \"thesis_bullets\": [\n    \"CGM leader benefits from rising global diabetes rates\",\n    \"Innovation in sensors maintains competitive edge\",\n    \"International expansion supports 14% revenue CAGR\",\n    \"Competition from Abbott pressures market share\",\n    \"Rich valuation needs sustained execution for upside\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Diabetes market expansion\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"New CGM product adoption\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Intensifying competitor pressure\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"International revenue growth\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"EBIT margin expansion\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Reimbursement changes\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Regulatory approvals\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Valuation multiple compression\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    }\n  ],\n  \"risks\": [\n    \"Intense competition from Abbott and Medtronic\",\n    \"Slowing revenue growth trajectory\",\n    \"Potential reimbursement cuts\",\n    \"High valuation leaves little margin for error\",\n    \"Supply chain or manufacturing issues\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.14,\n    \"ebit_margin_target\": 0.24,\n    \"wacc\": 0.095,\n    \"terminal_multiple\": 32\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 52,\n      \"prob\": 0.35,\n      \"notes\": \"Competition intensifies and growth slows sharply.\"\n    },\n    \"base\": {\n      \"target_price\": 82,\n      \"prob\": 0.45,\n      \"notes\": \"Steady execution on existing CGM pipeline.\"\n    },\n    \"bull\": {\n      \"target_price\": 105,\n      \"prob\": 0.2,\n      \"notes\": \"Accelerated adoption and new indications drive outsized growth.\"\n    }\n  },\n  \"method_notes\": \"DCF using 3y revenue CAGR, target EBIT margin, WACC and terminal EV/EBIT multiple. Balanced bull/bear drivers yield BUY with moderate 25% 12M upside. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "AI Equity Research Model",
          "risks": [
            "Intense competition from Abbott and Medtronic",
            "Slowing revenue growth trajectory",
            "Potential reimbursement cuts",
            "High valuation leaves little margin for error",
            "Supply chain or manufacturing issues"
          ],
          "ticker": "DXCM",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.45,
              "notes": "Steady execution on existing CGM pipeline.",
              "target_price": 82
            },
            "bear": {
              "prob": 0.35,
              "notes": "Competition intensifies and growth slows sharply.",
              "target_price": 52
            },
            "bull": {
              "prob": 0.2,
              "notes": "Accelerated adoption and new indications drive outsized growth.",
              "target_price": 105
            }
          },
          "confidence": 0.61,
          "assumptions": {
            "wacc": 0.095,
            "revenue_cagr_3y": 0.14,
            "terminal_multiple": 32,
            "ebit_margin_target": 0.24
          },
          "key_drivers": [
            {
              "driver": "Diabetes market expansion",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "New CGM product adoption",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Intensifying competitor pressure",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "International revenue growth",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "EBIT margin expansion",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Reimbursement changes",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Regulatory approvals",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Valuation multiple compression",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "DCF using 3y revenue CAGR, target EBIT margin, WACC and terminal EV/EBIT multiple. Balanced bull/bear drivers yield BUY with moderate 25% 12M upside. Not investment advice.",
          "current_price": 65.8,
          "recommendation": "BUY",
          "thesis_bullets": [
            "CGM leader benefits from rising global diabetes rates",
            "Innovation in sensors maintains competitive edge",
            "International expansion supports 14% revenue CAGR",
            "Competition from Abbott pressures market share",
            "Rich valuation needs sustained execution for upside"
          ],
          "target_price_6m": 74,
          "target_price_12m": 82
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "xai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "6ec1d725-52e5-924d-b337-bd8fde58ab3e",
            "usedFallbackChatCompletions": false
          },
          "sanityIssues": []
        },
        "latencyMs": 13104,
        "createdAt": "2026-04-09T05:20:30.734Z",
        "usage": {
          "inputTokens": 2697,
          "outputTokens": 2732,
          "costUsd": 0.049071
        }
      }
    ]
  }
}